214 related articles for article (PubMed ID: 26253730)
1. Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents.
Rosenstock J; Franco D; Korpachev V; Shumel B; Ma Y; Baughman R; Amin N; McGill JB;
Diabetes Care; 2015 Dec; 38(12):2274-81. PubMed ID: 26253730
[TBL] [Abstract][Full Text] [Related]
2. Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial.
Bode BW; McGill JB; Lorber DL; Gross JL; Chang PC; Bregman DB;
Diabetes Care; 2015 Dec; 38(12):2266-73. PubMed ID: 26180109
[TBL] [Abstract][Full Text] [Related]
3. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a basal insulin + 2-3 oral antihyperglycaemic drugs regimen versus a twice-daily premixed insulin + metformin regimen after short-term intensive insulin therapy in individuals with type 2 diabetes: The multicentre, open-label, randomized controlled BEYOND-V trial.
Pan Q; Li Y; Wan H; Wang J; Xu B; Wang G; Jiang C; Liang L; Feng W; Liu J; Wang T; Zhang X; Cui N; Mu Y; Guo L;
Diabetes Obes Metab; 2022 Oct; 24(10):1957-1966. PubMed ID: 35642463
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents.
Rosenstock J; Bergenstal R; Defronzo RA; Hirsch IB; Klonoff D; Boss AH; Kramer D; Petrucci R; Yu W; Levy B;
Diabetes Care; 2008 Nov; 31(11):2177-82. PubMed ID: 18678610
[TBL] [Abstract][Full Text] [Related]
6. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study.
Akturk HK; Snell-Bergeon JK; Rewers A; Klaff LJ; Bode BW; Peters AL; Bailey TS; Garg SK
Diabetes Technol Ther; 2018 Oct; 20(10):639-647. PubMed ID: 30207748
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial.
Raskin P; Heller S; Honka M; Chang PC; Boss AH; Richardson PC; Amin N
Diabetes Obes Metab; 2012 Feb; 14(2):163-73. PubMed ID: 21951325
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
[TBL] [Abstract][Full Text] [Related]
9. Understanding inhaled Technosphere Insulin: Results of an early randomized trial in type 1 diabetes mellitus.
McGill JB; Weiss D; Grant M; Jones MC; Kendall DM; Hoogwerf BJ
J Diabetes; 2021 Feb; 13(2):164-172. PubMed ID: 32737923
[TBL] [Abstract][Full Text] [Related]
10. A novel option for prandial insulin therapy: inhaled insulin.
Dailey G; Ahmad A; Polsky S; Shah V
Postgrad Med; 2016 Nov; 128(8):839-847. PubMed ID: 27580306
[TBL] [Abstract][Full Text] [Related]
11. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.
Yki-Järvinen H; Rosenstock J; Durán-Garcia S; Pinnetti S; Bhattacharya S; Thiemann S; Patel S; Woerle HJ
Diabetes Care; 2013 Dec; 36(12):3875-81. PubMed ID: 24062327
[TBL] [Abstract][Full Text] [Related]
12. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
Rodbard HW; Lingvay I; Reed J; de la Rosa R; Rose L; Sugimoto D; Araki E; Chu PL; Wijayasinghe N; Norwood P
J Clin Endocrinol Metab; 2018 Jun; 103(6):2291-2301. PubMed ID: 29688502
[TBL] [Abstract][Full Text] [Related]
13. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
Søfteland E; Meier JJ; Vangen B; Toorawa R; Maldonado-Lutomirsky M; Broedl UC
Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.
Ahmann A; Rodbard HW; Rosenstock J; Lahtela JT; de Loredo L; Tornøe K; Boopalan A; Nauck MA;
Diabetes Obes Metab; 2015 Nov; 17(11):1056-64. PubMed ID: 26179619
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).
Ahrén B; Leguizamo Dimas A; Miossec P; Saubadu S; Aronson R
Diabetes Care; 2013 Sep; 36(9):2543-50. PubMed ID: 23536584
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Roussel R; Duran-García S; Zhang Y; Shah S; Darmiento C; Shankar RR; Golm GT; Lam RLH; O'Neill EA; Gantz I; Kaufman KD; Engel SS
Diabetes Obes Metab; 2019 Apr; 21(4):781-790. PubMed ID: 30393950
[TBL] [Abstract][Full Text] [Related]
18. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
Ludvik B; Frías JP; Tinahones FJ; Wainstein J; Jiang H; Robertson KE; García-Pérez LE; Woodward DB; Milicevic Z
Lancet Diabetes Endocrinol; 2018 May; 6(5):370-381. PubMed ID: 29483060
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
Jabbour SA; Frías JP; Hardy E; Ahmed A; Wang H; Öhman P; Guja C
Diabetes Care; 2018 Oct; 41(10):2136-2146. PubMed ID: 30082326
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.
Davies MJ; Rosenstock J; Ali A; Russell-Jones D; Souhami E; Palmer K; Ji C; Niemoeller E; Skolnik N
Diabetes Obes Metab; 2022 Jan; 24(1):34-41. PubMed ID: 34617398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
